4results about How to "Low biocompatibility" patented technology

This application discloses the use of itaconic acid derivatives in the preparation of drugs for treating candidemia, belonging to the field of biomedical technology. The itaconic acid derivatives proposed in this application are dimethyl itaconic acid and / or 4-octyl itaconic acid. Dimethyl itaconic acid exhibits a dose-dependent therapeutic effect in model mice, with an optimal dose of 1200 mg / kg improving survival rate and reducing kidney damage; 4-octyl itaconic acid can enhance the anti-Candida albicans ability of macrophages and regulate the expression of inflammatory factors. The application of the itaconic acid derivatives proposed in this application in the treatment of candidemia works through immunomodulation, circumventing fungal resistance. Furthermore, the drugs are low in toxicity, have good biocompatibility, and use a universal experimental system, providing a new approach for the clinical treatment of candidemia with broad application prospects. This application also protects pharmaceutical compositions for treating candidemia with dimethyl itaconic acid and / or 4-octyl itaconic acid as active ingredients.

This application relates to the field of biomedical technology, and in particular to the application of N-acetylneuraminic acid in the preparation of drugs for treating methamphetamine addiction. This application is the first to discover the key role of N-acetylneuraminic acid (Neu5Ac) in the treatment of methamphetamine addiction, which can significantly reduce the CPP score in methamphetamine-addicted mice, demonstrating a good therapeutic effect on methamphetamine addiction. Furthermore, Neu5Ac can be synthesized endogenously, exhibiting advantages such as good biocompatibility and low toxicity.

The invention relates to the technical field of separation and extraction of natural products, in particular to a method for supercritical separation and extraction of astaxanthin, which comprises the following steps: (1) weighing raw material components in parts by weight; (2) mixing a biomass raw material rich in astaxanthin with the functionalized deep-eutectic solvent, and performing physical field enhanced extraction to obtain an extracting solution; (3) filtering the extracting solution through a vibrating membrane, and purifying to obtain a trapped fluid containing astaxanthin; and (4) carrying out supercritical CO2 back extraction on the trapped fluid, separating to obtain an astaxanthin product, and recovering the functional eutectic solvent. According to the method, continuous membrane separation and purification under the eutectic solvent system are realized, the purity of astaxanthin and the proportion of all-trans astaxanthin are maintained while the extraction rate of astaxanthin is increased, the solvent can be recycled after being recovered, and the production cost and waste liquid discharge are greatly reduced. All the raw materials are nontoxic and harmless, no organic solvent is used in the technological process, and good application prospects are achieved.

The application provides a stimulation system, comprising: a stimulation part, comprising a first stimulation electrode and a first control module connected with the first stimulation electrode, the first control module comprising a first coil; a first regulation part, comprising a first regulation unit, the first regulation unit comprising a first regulation coil; wherein the stimulation part is configured to be implanted in a to-be-stimulated part of a to-be-tested object, the first regulation part is configured to be placed outside the to-be-tested object, the first regulation part outputs energy to the first control module by coupling the first regulation coil with the first coil, and controls the stimulation degree of the first stimulation electrode through the first control module. In the application, the stimulation part is configured to be implanted in the to-be-stimulated part of the to-be-tested object, and the first regulation part is configured to be placed outside the to-be-tested object, that is, a distributed arrangement mode is adopted. Based on the setting, the biological compatibility, battery safety, packaging tightness and overall reliability of the first regulation part are reduced, the production cost of the stimulation system can be significantly reduced, and the clinical promotion is facilitated.